Hi, Sasha
Actually I believe the Ampligen "study" has been going on for years. But the thing is, it is cost recovery- meaning the patient has to pay for the cost of the medication (about $25,000 US dollars I believe). So it's not a regular drug study in that respect- bascially you can just enroll to receive Ampligen if you meet certain criteria, but it isn't free. What it says is:
"Detailed Description:
An Open-Label Study of Poly I: Poly C12U (Ampligen) in Patients with Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME). The FDA approved the study for cost recovery. Patients enrolled in the study are responsible for costs related to the therapy, e.g., drug cost, infusion cost, cost of supplies, diagnostic and other laboratory testing."
If it was free I'm sure the study would be filled with applicants within 1 hour of being posted online LOL.
The Rituximab study is only in Norway it looks like?
Other than that there doesn't seem to be much happening but the same studies I've been checking into for the past two years.